• Something wrong with this record ?

p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis

J. Lukas, CS. Sørensen, C. Lukas, E. Santoni-Rugiu, J. Bartek,

. 1999 ; 18 (27) : 3930-3935.

Language English Country England, Great Britain

Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15001045

p16ink4 and pRb, two components of a key G1/S regulatory pathway, and tumor suppressors commonly targeted in oncogenesis, are among the candidates for gene therapy of cancer. Wild-type p16 and a constitutively active pRb(delta cdk) mutant both blocked G1 in short-term experiments, but only p16 imposed a sustained G1 arrest. Unexpectedly, cells conditionally exposed to pRb(delta cdk) entered S phase after 2 days, followed by endoreduplication between days 4-6. The distinct phenotypes evoked by p16 vs pRb(delta cdk) appear mediated by cyclin E/CDK2 which, while active in the pRb(delta cdk)-expressing cells, became rapidly inhibited through restructuring diverse cyclin/CDK/p21 complexes by p16. These results provide novel insights into the roles of p16, pRb and cyclin E in G1/S control and multistep oncogenesis, with implications for gene therapy strategies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15001045
003      
CZ-PrNML
005      
20151014103605.0
007      
ta
008      
150112s1999 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/sj.onc.1202777 $2 doi
035    __
$a (PubMed)10435615
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Lukáš, Jiří $7 xx0094305
245    10
$a p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis / $c J. Lukas, CS. Sørensen, C. Lukas, E. Santoni-Rugiu, J. Bartek,
520    9_
$a p16ink4 and pRb, two components of a key G1/S regulatory pathway, and tumor suppressors commonly targeted in oncogenesis, are among the candidates for gene therapy of cancer. Wild-type p16 and a constitutively active pRb(delta cdk) mutant both blocked G1 in short-term experiments, but only p16 imposed a sustained G1 arrest. Unexpectedly, cells conditionally exposed to pRb(delta cdk) entered S phase after 2 days, followed by endoreduplication between days 4-6. The distinct phenotypes evoked by p16 vs pRb(delta cdk) appear mediated by cyclin E/CDK2 which, while active in the pRb(delta cdk)-expressing cells, became rapidly inhibited through restructuring diverse cyclin/CDK/p21 complexes by p16. These results provide novel insights into the roles of p16, pRb and cyclin E in G1/S control and multistep oncogenesis, with implications for gene therapy strategies.
650    _2
$a zvířata $7 D000818
650    12
$a kinasy CDC2-CDC28 $7 D042846
650    _2
$a nádorová transformace buněk $x genetika $x metabolismus $7 D002471
650    _2
$a cyklin-dependentní kinasa 2 $7 D051357
650    _2
$a inhibitor p16 cyklin-dependentní kinasy $x biosyntéza $x genetika $x fyziologie $7 D019941
650    _2
$a cyklin-dependentní kinasy $x biosyntéza $x metabolismus $7 D018844
650    _2
$a G1 fáze $x genetika $x fyziologie $7 D016193
650    _2
$a technika přenosu genů $7 D018014
650    _2
$a inhibitory růstu $x genetika $x fyziologie $7 D006131
650    _2
$a lidé $7 D006801
650    _2
$a osteosarkom $7 D012516
650    _2
$a protein-serin-threoninkinasy $x biosyntéza $x metabolismus $7 D017346
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a retinoblastomový protein $x biosyntéza $x genetika $x fyziologie $7 D016160
650    _2
$a S fáze $x genetika $7 D016196
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sørensen, C S
700    1_
$a Lukas, C
700    1_
$a Santoni-Rugiu, E
700    1_
$a Bártek, Jiří, $d 1953- $7 xx0046271
773    0_
$w MED00003600 $t Oncogene $x 0950-9232 $g Roč. 18, č. 27 (1999), s. 3930-3935
856    41
$u https://pubmed.ncbi.nlm.nih.gov/10435615 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150112 $b ABA008
991    __
$a 20151014103756 $b ABA008
999    __
$a ok $b bmc $g 1058133 $s 883763
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 1999 $b 18 $c 27 $d 3930-3935 $i 0950-9232 $m Oncogene $n Oncogene $x MED00003600
LZP    __
$a Pubmed-20150112

Find record

Citation metrics

Archiving options